Stemson Therapeutics, a San Diego, CA-based pre-clinical stage cell therapy company, closed a $15m Series A financing.
The round was led by DCVC Bio with participation from Genoa Ventures, AbbVie Ventures and other investors. In addition, Kiersten Stead, Ph.D., Co-Managing Partner at DCVC Bio and Jenny Rooke, Ph.D., Managing Director at Genoa Ventures will join Stemson’s Executive Chairman Matt Posard and Chief Executive Officer and co-founder Geoff Hamilton on the board of directors.
The company intends to use the funds to advance development of its proprietary therapeutic solution to cure hair loss.
Stemson Therapeutics is a pre-clinical stage cell therapy company with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cell (iPSC). The company uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss. The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia.